Recovery & injury

Several peptides are studied in the context of tissue repair and recovery: healing of tendons, ligaments, muscle, skin, and the gut lining. This is one of the most popular areas of interest, and also one where the gap between online claims and actual evidence is widest.

The honest summary: the recovery peptides documented here are predominantly supported by laboratory and animal research, not human clinical trials. BPC-157 and TB-500 are the two most commonly discussed (and often used together), but neither has completed human trials of the marketed compound, and both are research chemicals that are not approved for human use. KPV is a small anti-inflammatory fragment studied mainly in cell and animal models of gut and skin inflammation. GHK-Cu has the most human data of this group, but that evidence is largely topical/cosmetic (skin), not injectable repair.

Browse the individual entries below for the specific mechanisms, the studies behind them, their regulatory status, and honest safety notes. Nothing here is medical advice.

Conditions people ask about

Popular videos and peptide-vendor guides in this area promise to "reverse", "heal", or "cure" chronic pain and joint damage with a peptide protocol. That framing runs ahead of what the accessible literature can support: no compound on this site is an approved treatment for any condition below, and we found no controlled human evidence for the dramatic reversal claims in the sources we could search. A caveat worth stating plainly: not finding a supporting study here does not mean a claim is false. Much relevant work — paywalled journals, regional (including Russian and Chinese) literature, clinical practitioner experience, conference abstracts, and unpublished or proprietary data — is not indexed in the sources we searched, and absence of evidence is not evidence of absence. The notes below exist to answer common searches honestly — not to recommend a protocol, and not to assert an unverified claim as proven. Any of these conditions is a matter for a licensed clinician and proper diagnosis; a research peptide is not a substitute for that care.

Fibromyalgia

Popular videos and peptide-vendor guides frame fibromyalgia as a chronic-pain condition you can "manage" or "calm" with a peptide protocol, pointing to BPC-157's reported effects on serotonin, dopamine, and inflammation as if they translated into human pain relief. The evidence reality: no peptide is an approved treatment for fibromyalgia, and we found no controlled human trials of any peptide with fibromyalgia as an endpoint in the accessible literature — which is a limit of what is indexed, not a demonstration that none exist. The mechanistic story — modulation of dopaminergic and serotonergic signalling and downregulation of TNF-alpha/IL-6 — is drawn from animal models [Animal]; whether any of it produces symptom relief in people has not, as far as the reachable literature shows, been tested in a controlled human trial [Hypothesis]. Fibromyalgia is a real diagnosis that needs a licensed clinician; a research peptide is not a substitute. In this context the community discusses BPC-157, an unapproved research peptide whose fibromyalgia rationale (serotonin/dopamine modulation, lowered TNF-alpha and IL-6) rests on animal data [Animal], with no human trial for fibromyalgia or any chronic-pain condition found in the sources we searched; KPV, a small anti-inflammatory fragment (the C-terminal tail of alpha-MSH) studied in cell and animal models of inflammation [In vitro][Animal], often paired with BPC-157 on that anti-inflammatory rationale, with no controlled human evidence for fibromyalgia located; and TB-500, an unapproved thymosin-beta-4 fragment marketed for "recovery" whose documented tissue-repair and angiogenesis effects come from animal work [Animal], with no human evidence for fibromyalgia found in the accessible literature. Discussed, not proven either way.

Osteoarthritis / joint pain

High-claim content presents intra-articular BPC-157 (often stacked with TB-500) as a way to "heal" arthritic joints and "regrow cartilage", citing a knee-injection study as if joint degeneration were reversible with a peptide protocol. The evidence reality: no peptide is an approved treatment for osteoarthritis or joint pain. The single piece of human data usually cited is a small retrospective case series (12 patients) of intra-articular BPC-157 for chronic knee pain, described in a 2025 systematic review (Vasireddi et al.) — uncontrolled, no placebo group, and not a randomized controlled trial, so it cannot on its own establish efficacy or that cartilage regenerates [Human, low quality]; the cartilage-regeneration and anti-inflammatory rationale is otherwise preclinical [Animal][In vitro]. Osteoarthritis needs proper imaging and a licensed clinician; a research peptide is not a substitute. Compounds discussed here are BPC-157, whose only human joint data located is that small uncontrolled retrospective knee series [Human, low quality] — it reported pain relief in some individuals but cannot on its own prove efficacy or cartilage repair, with broader claims resting on animal tendon/tissue models [Animal]; TB-500, an unapproved thymosin-beta-4 fragment frequently paired with BPC-157 in the recovery context, whose cartilage-relevant effects (angiogenesis, stem-cell mobilization) are preclinical [Animal][In vitro] and for which we found no human clinical trials of the marketed fragment in the accessible literature; Thymosin beta-4, the parent regenerative peptide behind TB-500, studied for tissue repair and angiogenesis in animal and cell models [Animal][In vitro] and reaching only small early-stage human trials for other indications (ophthalmic and systemic), with any cartilage benefit extrapolated as a hypothesis [Hypothesis] and no controlled human evidence for osteoarthritis found in the sources we searched; and GHK-Cu, a copper peptide with the most human data of this group — but that evidence is topical/cosmetic skin work [Human, skin only], with joint mentions extrapolating its remodeling/anti-inflammatory rationale and no controlled human evidence for osteoarthritis located in the accessible literature.

Chronic kidney disease and dialysis

Do not stop or reduce prescribed blood-pressure or kidney medication on the basis of a video — this is the one entry on this page where that warning is not hedged. High-claim content frames chronic kidney disease (CKD) as roughly "90% reversible" with a peptide regenerative stack, while telling viewers that blood-pressure drugs, statins, and ACE inhibitors "destroy" the kidneys and that dialysis is a "business model." Each of those claims is false and, acted on, dangerous. No compound on this site is an approved treatment for CKD, and there is no controlled human evidence that any peptide — BPC-157, TB-500, GHK-Cu, MOTS-c, or NAD+ — reverses chronic kidney disease or renal fibrosis. The rationale is preclinical: BPC-157 protects rodent kidneys against acute injury [Animal]; NAD+ decline is implicated in renal fibrosis, with restoration reducing fibrosis in animal models [Animal][In vitro]; MOTS-c and GHK-Cu kidney claims are mechanistic or animal-level [Animal] (GHK-Cu's only substantial human data is topical skin work [Human, skin only]). Early regenerative-nephrology research is real but honestly early — the mitochondria-targeted peptide SS-31 (elamipretide) has animal diabetic-nephropathy data and human trials only for other indications [Animal], and the senolytic FOXO4-DRI reduced fibrosis in mice without restoring kidney function [Animal] — none of it justifies stopping real therapy, and the video's specific "reversal" citations could not be traced to any controlled human study.

The evidence points the opposite way from the video on every safety-critical claim. Hypertension is a major cause of CKD — the second leading cause of kidney failure after diabetes — so treating blood pressure protects the kidneys rather than harming them. ACE inhibitors and ARBs are guideline-recommended renoprotective therapy that slows loss of kidney function (RENAAL, Brenner et al., NEJM 2001; IDNT, Lewis et al., NEJM 2001; KDIGO 2024 guideline), SGLT2 inhibitors cut CKD progression by roughly a third with or without diabetes and improved survival (DAPA-CKD, Heerspink et al., NEJM 2020; EMPA-KIDNEY 2023), and the nonsteroidal MRA finerenone adds further benefit in diabetic CKD (FIDELIO-DKD, Bakris et al., NEJM 2020) [Human]. Statins are not nephrotoxic. Dialysis is life-sustaining renal replacement therapy — not a "business model" — and transplantation is the definitive treatment; the survival figures the video quotes reflect the severity of end-stage disease in older patients, not harm from dialysis. Established glomerulosclerosis and interstitial fibrosis are largely irreversible, so the realistic, proven goal is to slow progression and preserve function. CKD needs a nephrologist, lab monitoring (eGFR, urine albumin), and evidence-based treatment — and note that creatine, sometimes promoted for the kidneys, actually raises serum creatinine and confounds those very tests. A research peptide is not a substitute for that care, and stopping evidence-based therapy to chase an unproven protocol can cause irreversible kidney loss.

Slow or chronic non-healing injuries

High-claim content reframes a stubborn injury as "metabolic bankruptcy at a location" — the idea that healing is limited by cellular energy (ATP), not by rest, and that a stack of BPC-157, MOTS-c and NAD+ can cut recovery "from twelve months to ten-to-twelve weeks." There is a real kernel here worth acknowledging: wound and tissue healing is active, energy-demanding biological work rather than passive waiting, and genuinely chronic, non-healing wounds do involve impaired perfusion, hypoxia and reduced mitochondrial energy production (Eming et al., Sci Transl Med 2014) [Human/review]. But that kernel does not license the leap. No compound on this site is an approved treatment to accelerate healing, and no human trial shows any peptide — or the MOTS-c + NAD+ + BPC-157 combination — speeds recovery or shortens a twelve-month injury to ten weeks. The "reversal" and "70% faster" figures trace to citations we could not locate (the frequently-quoted "2021 systematic review of twelve studies" does not appear to exist), and several of the mechanistic references invoked are misattributed or impossible (one names a journal that ceased publishing two decades before the cited year). The compound evidence is what it is elsewhere on this site: BPC-157's tendon- and soft-tissue-healing data are animal (rat) work from a single research group [Animal], with only a small uncontrolled human case series in orthopaedics [Human, low quality]; MOTS-c is preclinical with no human injury-healing data [Animal]; and NAD+ is a redox coenzyme with limited human data and no evidence it accelerates wound healing [Human, limited]. Crucially, "it's not rest, it's energy" is a false dichotomy — appropriate rest, graded loading and rehabilitation, and treating the underlying cause all matter. And a truly slow or non-healing injury is itself a reason to see a clinician, not to self-treat: persistent non-healing can signal a structural tear, an infection (such as osteomyelitis), or a systemic problem — diabetes, peripheral arterial disease, or inflammatory arthritis — that needs imaging and diagnosis. A research peptide is not a substitute for that work-up, and this entry gives no protocol or dosing.